{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:22:30Z","timestamp":1788448950097,"version":"build-2803163510"},"reference-count":88,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bispecific antibodies (BsAbs) are emerging immunotherapeutics that simultaneously engage two distinct targets. This property provides unique mechanisms of action not achieved by conventional monoclonal antibodies, including cell\u2013cell bridging, modulation of multiple signaling pathways, and recruitment of diverse immune effector cells. Among these approaches, T-cell-engaging BsAbs are the most established modality. By simultaneously targeting a tumor-associated antigen and CD3 on T cells, they promote tumor-T-cell bridging, immune synapse formation, and major histocompatibility complex (MHC)-independent T-cell activation, and have shown marked clinical efficacy in several hematologic malignancies. More recently, their application has been extended to solid tumors, supported by encouraging data from clinical trials. Despite these advances, the efficacy and safety of BsAbs face several limitations, including short half-lives, tumor antigen escape, off-tumor toxicity, and insufficient T-cell activation due to the lack of costimulatory signals. To address these obstacles, BsAb structures have been modified in various ways, including Fc fusion, multispecific targeting, and armored designs that enhance T-cell function. These approaches aim to improve pharmacokinetics, specificity, and antitumor efficacy. In addition to these efforts, novel delivery platforms have been developed to further enhance the therapeutic potential of BsAbs. Engineered extracellular vesicles and nanoparticle-based systems may improve pharmacokinetics and tumor delivery, while enabling the integration of additional functional molecules beyond conventional BsAb formats. In this review, we summarize the basic principles of BsAbs, highlight key clinical developments, and discuss emerging strategies and remaining challenges in the development of next-generation BsAbs.<\/jats:p>","DOI":"10.1093\/intimm\/dxag044","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:15:10Z","timestamp":1786965310000},"source":"Crossref","is-referenced-by-count":0,"title":["Bispecific antibodies: current advances and future perspectives"],"prefix":"10.1093","author":[{"given":"Toshiya","family":"Hino","sequence":"first","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine , Shinjuku, Tokyo 160-8582 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine , Shinjuku, Tokyo 160-8582 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-6730","authenticated-orcid":false,"given":"Yuki","family":"Kagoya","sequence":"additional","affiliation":[{"name":"Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine , Shinjuku, Tokyo 160-8582 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026090310550928000_dxag044-B1","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1126\/science.132.3441.1770","article-title":"Properties of the major component of a peptic digest of rabbit antibody","volume":"132","author":"Nisonoff","year":"1960","journal-title":"Science"},{"key":"2026090310550928000_dxag044-B2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/0003-9861(61)90296-X","article-title":"Recombination of a mixture of univalent antibody fragments of different specificity","volume":"93","author":"Nisonoff","year":"1961","journal-title":"Arch Biochem Biophys"},{"key":"2026090310550928000_dxag044-B3","first-page":"12","article-title":"Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on","volume":"12","author":"Riethmuller","year":"2012","journal-title":"Cancer Immun"},{"key":"2026090310550928000_dxag044-B4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1084\/jem.119.1.151","article-title":"Serologic demonstration of dual specificity of rabbit bivalent hybrid antibody","volume":"119","author":"Fudenberg","year":"1964","journal-title":"J Exp Med"},{"key":"2026090310550928000_dxag044-B5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.114203","article-title":"Advances in the clinical application of bispecific antibodies in cancer therapy","volume":"28","author":"Zhou","year":"2025","journal-title":"iScience"},{"key":"2026090310550928000_dxag044-B7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/314628a0","article-title":"Hybrid antibodies can target sites for attack by T cells","volume":"314","author":"Staerz","year":"1985","journal-title":"Nature"},{"key":"2026090310550928000_dxag044-B8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/316354a0","article-title":"Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody","volume":"316","author":"Perez","year":"1985","journal-title":"Nature"},{"key":"2026090310550928000_dxag044-B9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026090310550928000_dxag044-B10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026090310550928000_dxag044-B11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026090310550928000_dxag044-B12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba2325","article-title":"Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy","volume":"12","author":"Waite","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026090310550928000_dxag044-B13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/1078-0432.CCR-24-1552","article-title":"A first-in-human study of cinrebafusp alfa, a HER2\/4-1BB bispecific molecule, in patients with HER2-positive advanced solid malignancies","volume":"31","author":"Piha-Paul","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026090310550928000_dxag044-B14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"key":"2026090310550928000_dxag044-B15","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T-cell bispecific antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026090310550928000_dxag044-B16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"2026090310550928000_dxag044-B17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","article-title":"Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy","volume":"20","author":"Zhang","year":"2023","journal-title":"Cancer Biol Med"},{"key":"2026090310550928000_dxag044-B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100641","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET","volume":"296","author":"Neijssen","year":"2021","journal-title":"J Biol Chem"},{"key":"2026090310550928000_dxag044-B19","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov"},{"key":"2026090310550928000_dxag044-B20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10585-020-10055-x","article-title":"Nintedanib and a bi-specific anti-VEGF\/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells","volume":"37","author":"Kovalchuk","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"2026090310550928000_dxag044-B21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"2026090310550928000_dxag044-B22","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-Cell Characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026090310550928000_dxag044-B23","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s41467-021-21445-4","article-title":"Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation","volume":"12","author":"Arenas","year":"2021","journal-title":"Nat Commun"},{"key":"2026090310550928000_dxag044-B24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jmb.2010.04.001","article-title":"Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion","volume":"399","author":"Johnson","year":"2010","journal-title":"J Mol Biol"},{"key":"2026090310550928000_dxag044-B25","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090310550928000_dxag044-B26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/jmbi.1999.3156","article-title":"Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics","volume":"293","author":"Kipriyanov","year":"1999","journal-title":"J Mol Biol"},{"key":"2026090310550928000_dxag044-B27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40291-024-00734-w","article-title":"Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors","volume":"28","author":"Gu","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"2026090310550928000_dxag044-B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"2026090310550928000_dxag044-B29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u2018Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng"},{"key":"2026090310550928000_dxag044-B30","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1080\/19420862.2016.1197457","article-title":"The use of CrossMAb technology for the generation of bi- and multispecific antibodies","volume":"8","author":"Klein","year":"2016","journal-title":"MAbs"},{"key":"2026090310550928000_dxag044-B31","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"MAbs"},{"key":"2026090310550928000_dxag044-B32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat5775","article-title":"Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2\/CD3","volume":"10","author":"Slaga","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026090310550928000_dxag044-B33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies","volume":"11","author":"Trinklein","year":"2019","journal-title":"MAbs"},{"key":"2026090310550928000_dxag044-B34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"2026090310550928000_dxag044-B35","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B36","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"key":"2026090310550928000_dxag044-B37","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B38","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"2026090310550928000_dxag044-B39","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B40","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"2026090310550928000_dxag044-B41","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026090310550928000_dxag044-B42","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B43","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"2026090310550928000_dxag044-B45","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026090310550928000_dxag044-B46","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B48","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"2026090310550928000_dxag044-B49","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"2026090310550928000_dxag044-B50","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"},{"key":"2026090310550928000_dxag044-B51","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B52","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","article-title":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial","volume":"407","author":"Falchi","year":"2026","journal-title":"Lancet"},{"key":"2026090310550928000_dxag044-B53","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026090310550928000_dxag044-B54","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"2026090310550928000_dxag044-B55","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B56","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"key":"2026090310550928000_dxag044-B57","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2026090310550928000_dxag044-B58","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B59","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B60","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S1470-2045(25)00287-6","article-title":"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study","volume":"26","author":"Elimova","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026090310550928000_dxag044-B61","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090310550928000_dxag044-B62","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026090310550928000_dxag044-B63","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026090310550928000_dxag044-B64","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.lungcan.2020.07.026","article-title":"International real-world study of DLL3 expression in patients with small cell lung cancer","volume":"147","author":"Rojo","year":"2020","journal-title":"Lung Cancer"},{"key":"2026090310550928000_dxag044-B65","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026090310550928000_dxag044-B66","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br J Cancer"},{"key":"2026090310550928000_dxag044-B67","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2531223","article-title":"Innovative strategies for T cell engagers for cancer immunotherapy","volume":"17","author":"Bergamaschi","year":"2025","journal-title":"MAbs"},{"key":"2026090310550928000_dxag044-B68","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/CPAA.S42689","article-title":"Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia","volume":"5","author":"Portell","year":"2013","journal-title":"Clin Pharmacol"},{"key":"2026090310550928000_dxag044-B69","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr Opin Biotechnol"},{"key":"2026090310550928000_dxag044-B70","doi-asserted-by":"publisher","first-page":"25612","DOI":"10.1074\/jbc.M109.027078","article-title":"Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives","volume":"284","author":"Stork","year":"2009","journal-title":"J Biol Chem"},{"key":"2026090310550928000_dxag044-B71","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2034355","article-title":"Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer","volume":"11","author":"Tapia-Galisteo","year":"2022","journal-title":"Oncoimmunology"},{"key":"2026090310550928000_dxag044-B72","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s43018-024-00821-1","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Carretero-Iglesia","year":"2024","journal-title":"Nat Cancer"},{"key":"2026090310550928000_dxag044-B73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004336","article-title":"Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186","volume":"10","author":"Dettling","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026090310550928000_dxag044-B74","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2322562","article-title":"A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy","volume":"16","author":"Frey","year":"2024","journal-title":"MAbs"},{"key":"2026090310550928000_dxag044-B75","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"2026090310550928000_dxag044-B76","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1172\/JCI31720","article-title":"APC-derived cytokines and T cell polarization in autoimmune inflammation","volume":"117","author":"Gutcher","year":"2007","journal-title":"J Clin Invest"},{"key":"2026090310550928000_dxag044-B77","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009563","article-title":"SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3\/CD137","volume":"12","author":"Kamikawa","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026090310550928000_dxag044-B78","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"key":"2026090310550928000_dxag044-B79","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010140","article-title":"Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer","volume":"13","author":"Sun","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026090310550928000_dxag044-B80","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1182\/blood.2023023381","article-title":"CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy","volume":"143","author":"Sam","year":"2024","journal-title":"Blood"},{"key":"2026090310550928000_dxag044-B81","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41375-021-01127-2","article-title":"Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy","volume":"35","author":"Alhallak","year":"2021","journal-title":"Leukemia"},{"key":"2026090310550928000_dxag044-B82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2409564122","article-title":"Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy","volume":"122","author":"Wang","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026090310550928000_dxag044-B83","doi-asserted-by":"publisher","first-page":"16413","DOI":"10.1021\/jacs.8b10047","article-title":"Reprogramming exosomes as nanoscale controllers of cellular immunity","volume":"140","author":"Cheng","year":"2018","journal-title":"J Am Chem Soc"},{"key":"2026090310550928000_dxag044-B84","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ymthe.2025.01.025","article-title":"Genetically reprogrammed exosomes for immunotherapy of acute myeloid leukemia","volume":"33","author":"Zhang","year":"2025","journal-title":"Mol Ther"},{"key":"2026090310550928000_dxag044-B85","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature15373","article-title":"Nanoparticle biointerfacing by platelet membrane cloaking","volume":"526","author":"Hu","year":"2015","journal-title":"Nature"},{"key":"2026090310550928000_dxag044-B86","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010005","article-title":"Plasma membrane-coated nanoparticles and membrane vesicles to orchestrate multimodal antitumor immunity","volume":"13","author":"Ito","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026090310550928000_dxag044-B87","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/eji.202048953","article-title":"Natural killer cell engagers in cancer immunotherapy: next generation of immuno-oncology treatments","volume":"51","author":"Demaria","year":"2021","journal-title":"Eur J Immunol"},{"key":"2026090310550928000_dxag044-B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-026-03057-9","article-title":"A logic-gated trispecific engager enhances macrophage killing of cancer cells in solid tumors","author":"Zhao","year":"2026","journal-title":"Nat Biotechnol"}],"container-title":["International Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/intimm\/advance-article-pdf\/doi\/10.1093\/intimm\/dxag044\/70676462\/dxag044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/intimm\/advance-article-pdf\/doi\/10.1093\/intimm\/dxag044\/70676462\/dxag044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:55:12Z","timestamp":1788447312000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/intimm\/advance-article\/doi\/10.1093\/intimm\/dxag044\/8763039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":88,"URL":"https:\/\/doi.org\/10.1093\/intimm\/dxag044","relation":{},"ISSN":["1460-2377"],"issn-type":[{"value":"1460-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"dxag044"}}